News about JSC Olainfarm Supervisory Council and Management Board
Juris Bundulis has been elected as a Chairperson of the Supervisory Council of JSC Olainfarm and Sandis Petrovičs has been elected as a Deputy Chairperson.
Supplementing previously published information about members of JSC Olainfarm Supervisory Council it is disclosed that Irina Maligina indirectly owns 1 097 051 shares of JSC Olainfarm.
The Supervisory Council of JSC Olainfarm approved Janis Leimanis as a Member of the Management Board. Board members Elena Bushberg, Signe Baldere-Sildedze and Raimonds Terentjevs continue to fulfil their duties at the Management Board of JSC Olainfarm.
Since 2020 Jānis Leimanis is a Member of the Supervisory Board of Latvijas Valsts Radio un Televīzijas Centrs and Rīgas Namu Pārvaldnieks Ltd. Since 2004 Member of the Management Board of JL Index Ltd, Private Ltd, responsible for business development and operational management. From February 2019 to February 2020, Member of the Management Board of CatchSmart Ltd, responsible for business development and operational management, implementation of the launch of programming services for public institutions and ministries. From 2016 to 2018, he was Chairman of the Management Board of Clean R Ltd, responsible for the strategic development and day-to-day management. From 2015 to present J. Leimanis is the Chairman of the Management Board of Jēkabpils Kokapstrāde Ltd, responsible for the strategic development of the company, reorganisation of operations, and ensuring the interests of shareholders.
Jānis Lemanis holds an Engineer’s Degree in Engineering and Industrial Management as well as Bachelor’s Degree from the Riga Technical University. He has the Association of Chartered Certified Accountants (ACCA) qualification. In addition, he is an authorised valuation expert of business interests, debt and equity instruments by the Register of Enterprises of Latvia. He has graduated from the Mini MBA program of Stockholm School of Economics in Riga (SSE Riga). He is also a Member of the Baltic Institute of Corporate Governance.
Janis Leimanis indirectly owns 10 521 shares of JSC Olainfarm.
Additional information:
Jānis Dubrovskis
Investor Relations Advisor of JSC Olainfarm
Phone: +371 29178878
Email: janis.dubrovskis@olainfarm.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Delårsrapport för januari – mars 202426.4.2024 08:00:00 CEST | Pressemelding
STOCKHOLM – den 26 april 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – mars 2024. Den fulla rapporten är tillgänglig på bolagets hemsida. ”Det har varit en stark inledning på 2024 där utvecklingen inom respektive portföljbolag löper enligt plan. Trots att vi haft ett motigt marknadsklimat har våra portföljbolag outtröttligt fortsatt driva utvecklingen av framtidens behandlingar vidare för att de så snabbt som möjligt ska komma patienterna till gagn. Vi ser fram emot tilltagande medvind och fler framsteg under året”, säger Viktor Drvota, VD, Karolinska Development. Väsentliga händelser under första kvartalet Portföljbolaget OssDsign rapporterade positiva data från den kliniska studien TOP FUSION. Top-line-resultaten, som granskats av oberoende radiologer, visar en fusionsgrad på 93 procent 12 månader efter operation med det nya nanosyntetiska bengraftet OssDsign Catalyst (januari 2024).Portföljbolaget AnaCardio erhöll SEK 50 mil
Interim Report - January-March 202426.4.2024 08:00:00 CEST | Press release
STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2024. The full report is available on the Company's website. “2024 has begun strongly with development within the respective portfolio companies proceeding according to plan. The adverse market climate we have previously experienced notwithstanding, our portfolio companies have continued tirelessly to advance the development of tomorrow’s treatments in order that patients can reap the benefits as quickly as possible. We look forward to an increasing tailwind and further progress during the year”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the first quarter The portfolio company OssDsign reported positive data from the clinical study TOP FUSION. Top-line results show a 93% spinal fusion rate at 12 months as assessed with CT by independent radiological review after surgery with the novel nanosynthetic bone graft OssDsign Catalyst
Solvay publishes notice of 2024 Annual General Meeting26.4.2024 08:00:00 CEST | Press release
Brussels, April 26, 2024, 8:00am CEST - regulated information Solvay today published materials for its next Ordinary General Shareholders’ Meeting, which will be held on Tuesday May 28, 2024 at the Event Lounge Conference Center, Boulevard Général Wahis 16/F, 1030 Brussels, at 10.30 am CEST. All documents relating to this meeting are now available on www.solvay.com. Shareholders will be asked to vote on a number of resolutions, among others: the approval of the financial statements for the financial year 2023; the approval of a total gross dividend of €2.43 per share; the approval of the revised directors’ remuneration; the renewal of the mandate, for a four-year period, of Ms Aude Thibaut de Maisières, as Director of the company; the appointment of EY regarding the assurance of sustainability information imposed by the EU Directive on sustainability reporting (Corporate Sustainability Reporting Directive); the approval of the change of control provision relating to the issuance of eur
Yara reports increased deliveries, lower prices and reduced GHG emission intensity in 1Q26.4.2024 08:00:00 CEST | Press release
First-quarter EBITDA1 was USD 435 million compared to USD 487 million in first quarter 2023. Net income was USD 16 million (USD 0.07 per share) compared with USD 105 (USD 0.41 per share) a year earlier. First-quarter 2024 highlights: EBITDA1 down 11% from 1Q23 mainly due to lower pricesTotal deliveries up 12% with European deliveries up 37% from 1Q23Reduced GHG emission intensity with implementation of key projectsHealthy demand growth and limited capacity additions indicate tightening supply-demand balance longer term “This quarter's results are down from same quarter last year as increased deliveries are offset by lower prices. Meanwhile, I am pleased to see that our efforts to decarbonize is yielding results. This is crucial to future-proof our business and be able to meet growing demand for low-carbon solutions”, said Svein Tore Holsether, President and Chief Executive Officer. Despite strong urea supply in 2023, prices are generally demand-driven with positive production margins f
Nexstim Plc Business Update Q1 202426.4.2024 08:00:00 CEST | Press release
Press release, Helsinki, 26 April 2024 at 9 AM (EEST) Nexstim Plc Business Update Q1 2024 Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) announces the key highlights of the Company’s business operations during Q1 2024. CEO Mikko Karvinen’s Business Update In line with our main strategic objective, we have continued to focus on profitable net sales growth. The sales of new systems at the beginning of this year has been slow, which is typical considering that hospitals' budgets focus on purchases towards the end of the year. We continued to grow our Diagnostics and Therapy Businesses with new system sales in our key markets in the United States and Europe. Between January and March 2024, we delivered a total of 2 new NBS systems and we are progressing according to our growth plans with our full year 2024 sales pipeline development. We have moved forward with projects that are crucial for the company's strategic competitive advantage, such as the development of our new NBS 6 diagnostics